Expanded access, also known as compassionate use, refers to the use of an investigational drug
outside of a clinical trial for patients with serious or life-threatening conditions who have exhausted
treatment options and are unable to participate in a clinical trial.
Repertoire Immune Medicines is committed to developing new therapies through well-designed
clinical trials and regulatory review, which we believe is the most appropriate way to evaluate safety
and efficacy and make new treatments available to patients as quickly and responsibly as possible.
Information about Repertoire’s clinical trial of RPTR-1-201 is available at www.clinicaltrials.gov
under NCT07293754.
At this time, Repertoire does not offer expanded access or compassionate use for RPTR-1-201.
Expanded access may be considered in the future only after sufficient safety and efficacy
information has been obtained through clinical trials.
For additional information regarding the status of our investigational drugs, or to submit an
expanded access request, please contact Repertoire Immune Medicines at eap@repertoire.com.
Repertoire will acknowledge receipt of a request within ten (10) business days.